PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23195915-0	2013	Estimation of safe and effective dose of vancomycin in MRSA-infected patients using serum cystatin C concentrations.	Vancomycin	41-51	cystatin C	Homo sapiens	90-100	
23195915-1	2013	OBJECTIVE: To utilize serum cystatin C (CysC) concentration to identify the daily dosage regimen of vancomycin (Van) for the treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections.	Vancomycin	100-110	cystatin C	Homo sapiens	28-38	
23195915-1	2013	OBJECTIVE: To utilize serum cystatin C (CysC) concentration to identify the daily dosage regimen of vancomycin (Van) for the treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections.	Vancomycin	100-110	cystatin C	Homo sapiens	40-44	
23195915-1	2013	OBJECTIVE: To utilize serum cystatin C (CysC) concentration to identify the daily dosage regimen of vancomycin (Van) for the treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections.	Vancomycin	112-115	cystatin C	Homo sapiens	28-38	
23195915-1	2013	OBJECTIVE: To utilize serum cystatin C (CysC) concentration to identify the daily dosage regimen of vancomycin (Van) for the treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections.	Vancomycin	112-115	cystatin C	Homo sapiens	40-44	
23195915-12	2013	CysC can estimate the daily dose of Van, and may improve therapeutic success rates of MRSA-infected patients.	Vancomycin	36-39	cystatin C	Homo sapiens	0-4